Growth hormone secretagogues

Bibliography

• DE BOER H, BLOK G-J, VAN DER VEEN E: Clinical aspectsof growth hormone deficiency in adults. Endocr. Rev. (1995) 16:63–86.
   PubMed Web of Science ®Google Scholar
• SAENGER P. Editorial: oral growth hormonesecretagogues-better than Alice in Wonderland's growth elixir. J. Olin. Endocrinol. Metab. (1996) 81:2773–2775.
   PubMed Web of Science ®Google Scholar
• CASANUEVA F, DIEGUEZ C: Growth hormone secreta-gogues: physiological role and clinical utility. Trends Endocrinol. Metab. (1999) 10:30–38.
   PubMed Web of Science ®Google Scholar
• FAZIO S, SABATINI D, CAPALDO B et al.: A preliminary study of growth hormone in the treatment of dilated cardiomyopathy. N Engl. J. Med. (1996) 334:809–814.
   PubMed Web of Science ®Google Scholar
• JOHANNSSON G, MARIN P, LONN L et al.: G11 treatment of abdominally obese men reduces abdominal fat mass, improves glucose and lipoprotein metabolism and reduces diastolic blood pressure. J. Olin. Endocrinol. Metab. (1997) 82:727–734.
   PubMed Web of Science ®Google Scholar
• SMITH R, VAN DER PLOEG L, HOWARD A et al.:Peptidomimetic regulation of growth hormone secretion. Endocr. Rev. (1998) 18:621–645.
   Google Scholar
• •Review focused on the research programme of Merck.
   Google Scholar
• OSCARSSON J, JOHANNSSON G, JOHANSSON J-O, LUNDBERG P-A, LINDSTEDT G, BENGTSSON B-A: Diurnal variation in serum insulin-like growth factor (IGF)-I and IGF binding protein-3 concentrations during daily subcutaneous injections of recombinant human growth hormone in GH-deficient adults. Olin. Endocrinol. (1997) 46:63–68.
   PubMed Web of Science ®Google Scholar
• FROHMAN L, JANSSON J-O: Growth hormone-releasing hormone. Endocr. Rev. (1986) 7:223–253.
   PubMed Web of Science ®Google Scholar
• BOWERS C, MOMANY F, REYNOLDS G, HONG A: A study on the regulation of growth hormone release from the pituitaries of rats in vitro. Endocrinology (1981) 108:1071–1080.
   PubMed Web of Science ®Google Scholar
• MOMANY F, BOWERS C, REYNOLDS G, CHANG D, HONG A, NEWLANDER K: Design, synthesis and biological activity of peptides which release growth hormone in vitro. Endocrinology (1981) 108:31–39.
   PubMed Web of Science ®Google Scholar
• BOWERS C, MOMANY F, REYNOLDS G, HONG A: On the in vitro and the in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. Endocrinology (1984) 114:1537–1545.
   PubMed Web of Science ®Google Scholar
• BOWERS C, MOMANY F, REYNOLDS G, HONG A, NEWLANDER K: Conformational energy studies and in vitro activity data on active G11 releasing peptides. Endocrinology (1984) 114:1531–1537.
   PubMed Web of Science ®Google Scholar
• GOTH MI, LYONS CE, CANNY BJ, THORNER MO: Pituitary adenylate cyclase activating polypeptide, growth hormone (Gil)-releasing peptide and GH-releasing hormone stimulate G11 release through distinct pituitary receptors. Endocrinology (1992) 130:939–944.
   PubMed Web of Science ®Google Scholar
• CODD E, SHU A, WALKER R: Binding of growth hormone releasing hexapeptide to specific hypotha-lamic and pituitary binding sites. Neuropharmacology (1989) 28:1139–1144.
   PubMed Web of Science ®Google Scholar
• DICKSON S, LENG G, ROBINSON I: Systemic administra-tion of growth hormone-releasing peptide activates hypothalamic arcuate neurons. Neuroscience (1993) 53:303–306.
   PubMed Web of Science ®Google Scholar
• DICKSON S, LUCKMAN S: Induction of c-fos mRNA inNPY and GRF neurones in the rat arcleus nucleus following systemic injection of the growth hormone, GHRP-6. Endocrinology (1997) 138:771–777.
   PubMed Web of Science ®Google Scholar
• GUILLAUME V, MAGNAN E, CATALDI M et al.: Growth hormone (GM-releasing hormone secretion is stimulated by a new Gil-releasing hexapeptide in sheep. Endocrinology (1994) 135:1073–1076.
   PubMed Web of Science ®Google Scholar
• BOWERS C: Gil releasing peptides-structure and kinetics. J. Pediatr. Endocrinol. (1993) 6: 21–31.
   PubMed Web of Science ®Google Scholar
• POPOVIC V, DAMJANOVIC S, MIMIC D, DJUROVIC M, DIEGUEZ C, CASANUEVA F: Blocked growth hormone-releasing peptide (GHRP-6)-induced Gil secretion and absence of the synergistic action of GHRP-6 plus Gil-releasing hormone in patients with hypothalamo-pituitary disconnection: evidence that GHRP-6 main action is exerted at the hypothalamic level. J. Clin. Endocrinol. Metab. (1995) 80:942–947.
   PubMed Web of Science ®Google Scholar
• LEAL-CERRO A, GARCIA E, ASTORGA R, CASANUEVA F,DIEGUEZ C: Growth hormone (Gil) responses to the combined administration of Gil-releasing hormone plus Gil-releasing peptide 6 in adults with Gil deficiency. Eur. J. Endocrinol. (1995) 132:712–715.
   PubMed Web of Science ®Google Scholar
• LUCHE S, CAMBIASO P, MEROLA B et al.: The effect ofhexarelin on growth hormone (Gil) secretion in patients with Gil deficiency. J. Clin. Endocrinol Metab. (1995) 80:2692–2696.
   PubMed Web of Science ®Google Scholar
• THORNER M, ROCHICCIOLI P, COLLE M et al: Once dailysubcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone deficient children during first year of therapy. J. Clin. Endocrinol. Metab. (1996) 81:1189–1196.
   PubMed Web of Science ®Google Scholar
• LARON Z, FRENKEL J, DEGHENGHI R, ANIN S, KLINGER B,SIBERGELD A: Intranasal administration of the GHRP hexarelin accelerates growth in short children. Clin. Endocrinol. (1995) 43:631–635.
   PubMed Web of Science ®Google Scholar
• •Long-term GHS treatment in selected children of short stature.
   Google Scholar
• PIHOKER C, BADGER T, REYNOLDS G, BOWERS C: Treatment effects of intranasal growth hormone releasing peptide-2 in children with short stature. J. Endocrinol. (1997) 155:79–86.
   PubMed Web of Science ®Google Scholar
• •Long-term GHS treatment in selected children of short stature.
   Google Scholar
• MERICQ V, CASSORLA F, SALAZAR T eta].: Effects of eight treatment with graded doses of a growth hormone (Gil)-releasing peptide in Gil-deficient children. J. Clin. Endocrinol. Metab. (1998) 83:2355–2360.
   Google Scholar
• •Long-term GHS treatment in selected children with GH deficiency.
   Google Scholar
• CHAPMAN I, PESCOVITZ O, MURPHY G et al.: Oral administration of growth hormone (Gil) releasing peptide-mimetic MK-677 stimulates the Gil/insulin-like growth factor-I axis in selected Gil-deficient adults. J. Clin. Endocrinol Metab. (1997) 82:3455–3463.
   PubMed Web of Science ®Google Scholar
• TAKALA J, RUOKONEN E, WEBSTER NR et al.: Increasedmortality associated with growth hormone treatment in critically ill patients. N. Engl. J. Med. (1999) 341:785–792.
   PubMed Web of Science ®Google Scholar
• VAN DEN BERGHE G: Growth hormone secretagogues in critical illness. Horm Res. (1999) 51 (Suppl. 3):21–28.
   Google Scholar
• BENGTSSON B-A, KOPPESCHAAR HP, ABS R et al.: Growth hormone replacement therapy is not associ-ated with any increase in mortality. KIMS Study Group. Clin. Endocrinol. Metab. (1999) 84:4291–4292.
   PubMed Web of Science ®Google Scholar
• SVENSSON J, LONN L, JANSSON J -O et al.: Two-month treatment of obese subjects with the oral growth hormone (Gil) secretagogue MK-677 increases Gil secretion, fat-free mass and energy expenditure. J.. Metab. (1998) 83:362–369.
   Google Scholar
• MULLER EE, LOCATELLI V, COCCHI D: Neuroendocrinecontrol of growth hormone secretion. Physiol. Rev. (1999) 79:511–607.
   PubMed Web of Science ®Google Scholar
• AKMAN M, GIRARD M, O'BRIEN L, HO A, CHIK C: Mechanisms of action of a second generation growth hormone-releasing peptide (Ala-His-D-6Nal-Ala-Trp-o-Phe-Lys-NH2) in rat anterior pituitary cells. Endocrinology (1993) 132:1286–1291.
   PubMed Web of Science ®Google Scholar
• HOWARD A, FEIGHNER S, CULLY D et al.: A pituitarygland and hypothalamic receptor that functions in growth hormone release. Science (1996) 273:974–977.
   PubMed Web of Science ®Google Scholar
• •The GHS receptor is described.
   Google Scholar
• GUAN X-M, YU H, PALYHA O, et al.: Distribution of encoding the growth hormone secretagogue receptor in brain and peripheral tissues. Mol. Brain Res. (1997) 48:23–29.
   Google Scholar
• ONG H, MCNICOLL N, ESCHER E et al: Identification of a pituitary growth hormone-releasing peptide (GHRI) receptor subtype by photoaffinity labeling. Endocri-nology (1998) 139:432–435.
   PubMed Web of Science ®Google Scholar
• BODART V, BOUCHARD J, MCNICOLL N et al: Identifica-tion and characterization of a new growth-hormone-releasing peptide receptor in the heart. Circ. Res. (1998) 85:796–802.
   Web of Science ®Google Scholar
• KOJIMA M, HOSODA H, DATE Y, NAKAZATO M, MATSUO H, KANGAWA K: Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. (1999) 402:656–660.
   PubMed Web of Science ®Google Scholar
• ••The endogenous ligand (ghrelin) is described.
   Google Scholar
• BOWERS C, SARTOR A, REYNOLDS G, BADGER T: On the of the growth hormone-releasing hexapep-, GHRP-6. Endocrinology (1991) 128:2027–2035.
   PubMedGoogle Scholar
• VAN DEN BERGHE G, WOUTERS P, WEEKERS F et al.: of pituitary hormone release and metabolic improvement by infusion of growth hormone-releasing peptide and thyrotropin-releasing hormone in patients with protracted critical illness. J. Clin. Endocrinol. Metab. (1999) 84:1311–1323.
   Google Scholar
• •Short-term GHRP-2 administration in patients with prolonged critical illness.
   Google Scholar
• SHAH N, EVANS W, BOWERS C, VELDHUIS J: Tripartite activation of the human growth hormone (Gil) axis in women by continuous Gil-releasing peptide infusion: pulsatile, entropic and nyctohemeral mechanisms. J. Clin. Endocrinol. Metab. (1999) 84:210–2150.
   Web of Science ®Google Scholar
• CELLA S, CERRI C, DANIEL S et al.: Sixteen weeks of hexarelin therapy in aged dogs: effects on the somato-tropic axis, muscle morphology and bone metabo-lism. J. Gerontol. A Biol. ScL Med. ScL (1996) 51:B439–B447.
   Web of Science ®Google Scholar
• DE GENNARO COLONNA V, ROSSONI G, BERNAREGGI M, MULLER E, BERTI F: Cardiac ischemia and impairment of vascular endothelium function in hearts from growth hormone-deficient rats: protection by hexarelin. Eur. J. Pharmacol. (1997) 334:201–207.
   PubMed Web of Science ®Google Scholar
• DE GENNARO COLONNA V, ROSSONI G, BERNAREGGI M, MULLER E, BERTI F: Hexarelin, a growth hormone-releasing peptide, discloses protectant activity against cardiovascular damage in rats with isolated growth hormone deficiency. Cardiologia (1997) 42:1165–1172.
   PubMedGoogle Scholar
• ROSSONI G, DE GENNARO COLONNA V, BERNAREGGI M, POLVANI G, MULLER E, BERTI F: Protectant activity of hexarelin or growth hormone against postischemic ventricular dysfunction in hearts from aged rats. J. Cardiovasc. PharmacoL (1998) 32:260–265.
   PubMed Web of Science ®Google Scholar
• TIVESTEN A, BOLLANO E, CAIDAHL K et al.: The growth hormone secretagogue hexarelin improves cardiac function in rats after experimental myocardial infarc-tion. Endocrinology (2000) 141:60–66.
   PubMed Web of Science ®Google Scholar
• SIBILIA V, COCCHI D, PAGANI F et al.: Hexarelin, a growth hormone-releasing peptide, counteracts bone loss in gonadectomized rats. Growth Horm. IGF Res. (1999) 9:219–227.
   PubMed Web of Science ®Google Scholar
• RAHIM A, O'NEILL P, SHALET S: Growth hormone status during long-term hexarelin therapy. J. Clin. Endocrinol Metab. (1998) 83:1644–1649.
   PubMed Web of Science ®Google Scholar
• KUBIAK T, FRIEDMAN A, MOSELEY W: Synthetic analogues of growth hormone releasing factor with improved pharmaceutical properties. In: Growth hormone secretagogues. Bercu BB, Walker RF (Eds.), Springer-Verlag, New York, USA (1996):31–52.
   Google Scholar
• CHAPMAN I, BACH M, VAN CAUTER E et al.: Stimulation of the growth hormone (GI-1)- Insulin-like growth factor-I axis by daily oral administration of a Gil secretagogue (MK-677) in healthy elderly subjects. J.. Metab. (1996) 81:4249–4257.
   Google Scholar
• COPINSCHI G, LRPROULT R, VAN ONDERBERGEN A et al.: Prolonged oral treatment with MK-677, a novel growth hormone secretagogue, improves sleep quality in man. Neuroendocrinology (1997) 66:278–286.
   Google Scholar
• MURPHY M, PLUNKETT L, GERTZ B et al.: MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism. J. Clin. Endocrinol. Metab. (1998) 83:320–325.
   PubMed Web of Science ®Google Scholar
• SVENSSON J, OHLSSON C, JANSSON J -O et al.: Treatment with the oral growth hormone secretagogue MK-677 increases markers of bone formation and bone resorption in obese young males. J. Bone Miner. Res. (1998) 13:1158–1166.
   Google Scholar
• SVENSSON J, JANSSON J -O, OTTOSSON M et al.: Treatment of obese subjects with the oral growth hormone secretagogue MK-677 affects serum concen-trations of several lipoproteins, but not lipopro-tein(a). j Gun. Endocrinol. Metab. (1999) 84:2028–2033.
   PubMed Web of Science ®Google Scholar
• MURPHY M, BACH M, PLOTKIN D et al: Oral administra-tion of the growth hormone secretagogue MK-677 increases markers of bone turnover in healthy and functionally impaired elderly adults. J. Bone Miner. Res. (1999) 14:1182–1188.
   PubMed Web of Science ®Google Scholar
• OHLSSON C, BENGTSSON B-A, ISAKSSON O, ANDREASSEN T, SLOOTWEG M: Growth hormone and bone. Endocr. Rev. (1998) 19:55–79.
   PubMed Web of Science ®Google Scholar
• CLARK R, THOMAS G, MORTENSEN D et al: Growth hormone secretagogues stimulate the hypothalamic-pituitary-adrenal axis and are diabetogenic in the Zucker diabetic fatty rat. Endocrinology (1997) 138:4316–4323.
   PubMed Web of Science ®Google Scholar
• RAUN K, HANSEN B, JOHANSEN N et al: Ipamorelin, thefirst selective growth hormone secretagogue. Eur. J. Endocrinol. (1998) 139:552–561.
   PubMed Web of Science ®Google Scholar
• SEHESTED HANSEN B, RAUN K, KRAMER NIELSEN K et al.:Pharmacological characterisation of a new oral Gil secretagogue, NN703. Eur. J. Endocrinol. (1999) 141:180–189.
   Google Scholar
• JOHANSEN P, NOWAK J, SKJAERBAEK C et al.: Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Horm. IGF Res. (1999) 9:106–113.
   PubMed Web of Science ®Google Scholar
• SVENSSON J, LALL S, DICKSON S et al.: The growthhormone (GI-1) secretagogues ipamorelin and Gil-releasing peptide-6 increase bone mineral content in adult female rats. J. Endocrinol. (2000) 165:569–577.
   PubMed Web of Science ®Google Scholar
• MALMLOF K, JOHANSEN P, HAAHR P, WILKEN M, OXLUND H: Methylprednisolone does not inhibit the release of growth hormone after intravenous injection of a novel growth hormone secretagogue in rats. Growth Horm. IGF Res. (1999) 9:445–450.
   PubMed Web of Science ®Google Scholar
• PAN L: Biological activities of a new Gil secretagogue.Proceedings of the 3rd International Symposium on Growth Hormone Secretagogues. Keystone, Colorado, USA (2000) (Abstract).
   Google Scholar